Clinical trial
Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
NCT01288170 is registered in ClinicalTrials.gov with Erempharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
- Lead sponsor
- Erempharma
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- February 28, 2010
- Completion date
- Not reported
- Enrollment
- 12 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.